NK cell therapy to help control multiple myeloma after initial treatment
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This Phase 2 trial tests using your own immune cells (NK cells) alone or with isatuximab as “maintenance” treatment to help multiple myeloma stay under control after initial therapy. It may help lengthen the time until the disease grows again by boosting your immune response and targeting myeloma cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active multiple myeloma (not just a slow/asymptomatic form).
- Your disease must be measurable on lab tests (M-protein in blood or urine, or abnormal free light chain results).
- You are age 18 or older and able to give written consent.
- Your overall health/function is good (ECOG score 0 or 1).
- You will start the study around the time of planned high-dose chemotherapy (newly diagnosed patients considered for this).
- You must meet the “maintenance after response” timing rules after high-dose treatment (at least a partial response).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy made from donor cells, called CAR-NK cells. The cells are designed to find and attack myeloma cells. The goal is to see if this treatment can help people whose myeloma has not responded to multiple prior treatments.
This trial tests an experimental therapy using immune cells (CAR-NK cells) designed to target and kill cancer cells in people with multiple myeloma or plasma cell leukemia that has returned or stopped responding to treatment. The goal is to see if it is safe and effective.
This trial tests a new cell therapy (KSVCBD) for people with multiple myeloma that has returned or not responded to other treatments. It may help if your cancer cells have certain markers, CD19 or BCMA.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This trial tests a new type of treatment using your own immune cells (called CAR-T cells) that target two proteins on myeloma cells: BCMA and GPRC5D. It's for people whose myeloma has come back or stopped responding to standard treatments, and who may have few other options left.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.